News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

MethylGene to Present MGCD290 Data at the 2012 Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)


9/4/2012 1:26:54 PM

Montreal, Canada. September 4, 2012 – MethylGene Inc. (TSX:MYG) today announced that preclinical data for its novel, clinical-stage antifungal MGCD290, will be presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), taking place in San Francisco, California from September 9 to 12, 2012. This poster presentation will highlight the efficacy of MGCD290 when combined with fluconazole in a mouse model of systemic candidiasis.

Poster Presentation

MGCD290, an Oral Fungal Hos2 Inhibitor, Enhances the Antifungal Properties of Fluconazole following Multiple or Single Oral Dose Administration in Pre- and Post-Infection Settings

Date and Time: Tuesday September 11, 11:15 AM to 1:15 PM (PDT)

Session: Clinical Mycology II

Presentation No.: M-1711

Location: Exhibit Halls A-C

About MGCD290

MGCD290 is a first-in-class, orally available, small molecule inhibitor of the fungal enzyme Hos2. Current antifungal therapies suffer from a number of shortcomings including gaps in the coverage of fungal pathogens, acquisition of resistance, toxicity and drug-drug interactions. MGCD290 is initially being developed as an adjunct or combination product with fluconazole, the most widely used triazole antifungal. In vitro, MGCD290 in combination with fluconazole reverses fluconazole resistance (primary and acquired) in a wide range of fungal species, including Candida glabrata. MGCD290 has completed multiple Phase I studies in healthy adult volunteers and has shown an excellent safety profile without drug-drug interactions, either as monotherapy or in combination with fluconazole. A randomized, controlled Phase II study in moderate to severe acute VVC is underway.

About MethylGene

MethylGene Inc. (TSX:MYG) is a small molecule drug development company that is advancing two novel therapeutics for cancer and infectious disease in human clinical trials. The Company’s lead product candidates are: MGCD290, an oral antifungal agent targeting the fungal Hos2 enzyme that is currently in Phase II trials for vulvovaginal candidiasis, and MGCD265, an oral Met/VEGF receptor kinase inhibitor that is in Phase I/II clinical trials for solid tumor cancers. MethylGene owns all rights to its lead product candidates, and has partnerships with Otsuka Pharmaceutical Co. Ltd., Taiho Pharmaceutical Co. Ltd., and EnVivo Pharmaceuticals, Inc. for its other pipeline programs.

Investor Relations Contact:

Joseph Walewicz, CFA

Vice President, Business & Corporate Development

MethylGene Inc.

Phone: 514-337-3333 ext. 373

ir@methylgene.com

www.methylgene.com

Thomas Hoffmann

Vice President

The Trout Group LLC

Phone: 646-378-2931

thoffmann@troutgroup.com

www.troutgroup.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES